Corticosteroids in chronic inflammatory demyelinating polyneuropathy : a retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone by G. van Lieverloo et al.
Vol:.(1234567890)
Journal of Neurology (2018) 265:2052–2059
https://doi.org/10.1007/s00415-018-8948-y
1 3
ORIGINAL COMMUNICATION
Corticosteroids in chronic inflammatory demyelinating 
polyneuropathy
A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, 
pulsed dexamethasone, and pulsed intravenous methylprednisolone
G. G. A. van Lieverloo1  · S. Peric2 · P. E. Doneddu3 · F. Gallia3 · A. Nikolic2 · L. Wieske1 · C. Verhamme1 · 
I. N. van Schaik1 · E. Nobile‑Orazio3 · I. Basta2 · F. Eftimov1
Received: 2 May 2018 / Revised: 14 June 2018 / Accepted: 18 June 2018 / Published online: 2 July 2018 
© The Author(s) 2018
Abstract
Background Chronic inflammatory demyelinating polyneuropathy (CIDP) can be treated with corticosteroids or intravenous 
immunoglobulins. Various corticosteroid regimens are currently used in CIDP, but it is unknown whether they are equally 
efficacious. In this retrospective study, we compared efficacy and safety of three corticosteroid regimens in CIDP patients.
Methods We included treatment naïve patients that fulfilled the EFNS/PNS criteria for CIDP. Patients were treated with 
corticosteroids according to the local protocol of three CIDP expertise centres. Corticosteroid regimens consisted of daily oral 
prednisolone, pulsed oral dexamethasone, or pulsed intravenous methylprednisolone. Outcomes were number of responders 
to treatment, remission rate of treatment responders, overall probability of 5-year remission, and the occurrence of adverse 
events.
Results A total of 125 patients were included. Sixty-seven (54%) patients received daily prednisone or prednisolone, 37 (30%) 
pulsed dexamethasone, and 21 (17%) pulsed intravenous methylprednisolone. Overall, 60% (95% CI 51–69%) responded to 
corticosteroids, with no significant difference between the three treatment regimens (p = 0.56). From the 75 responders, 61% 
(95% CI 50–73%) remained in remission, during a median follow-up of 55 months (range 1–197 months). The probability 
of responders reaching 5-year remission was 55% (95% Cl 44–70%), with no difference between the three groups. Adverse 
events leading to a change in treatment occurred in ten patients (8%). Two patients had a serious adverse event.
Conclusion Corticosteroids lead to improvement in 60% of patients and to remission in 61% of treatment responders. There 
were no differences between treatment modalities in terms of efficacy and safety.
Keywords CIDP · (Cortico)steroids · Immunosuppressive treatment · Peripheral nerve disorder
Introduction
Chronic inflammatory demyelinating polyneuropathy 
(CIDP) is an immune-mediated disease of the peripheral 
nerves that causes sensory and motor impairment. Approxi-
mately 80% of patients respond well to corticosteroids, intra-
venous immunoglobulin (IVIg), or plasma exchange [1–3]. 
The decision which treatment to start first in an individual 
patient is difficult as there are no good predictors of treat-
ment response.
Both corticosteroids and IVIg have their advantages and 
drawbacks. Corticosteroids are easy to administer, cheap, 
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and may lead to long-term remission in CIDP more often 
compared to IVIg [4–7].
However, there are concerns with regard to safety during 
long-term treatment with corticosteroids. Studies suggest 
that corticosteroids given in pulses during a relatively short 
period of time have lower rates of serious side effects than 
long-term daily oral use of corticosteroids [8–10]. To avoid 
adverse events associated with corticosteroids, most patients 
in high-income countries are treated with IVIg, which is 
associated with less adverse events. IVIg has a fast mode 
of action, but has to be administrated by regular infusions 
[11]. IVIg is expensive and, therefore, not widely available.
Various corticosteroid regimens are currently used in 
CIDP and it is unknown whether one regimen is superior 
over others. Response and remission rates of corticosteroids 
in CIDP have so far been described in studies with small 
number of patients or without comparison between treat-
ment regimens [4, 5, 7, 12]. In this retrospective study, we 
reviewed the response and remission rates, and the occur-
rence of adverse events of three different corticosteroid treat-
ment protocols.
Materials and methods
Study design and patients
Data were collected retrospectively from treatment naive 
CIDP patients from year 2000 onwards, in three large CIDP 
centres in Serbia, The Netherlands, and Italy using a pre-
defined questionnaire. For screening of patients, we used 
only the periods in which corticosteroids were considered 
the first-line treatment according to local protocols. Patients 
needed to fulfil the definite, probable, or possible EFNS/
PNS criteria for CIDP [10]. Data were collected anony-
mously from CIDP databases and hospital charts. Approval 
by the ethics committee was not acquired under applicable 
national legislation.
Treatment protocols
In all three centres, corticosteroids were considered the first-
line treatment. Patients with severe disability, contraindi-
cation for corticosteroids, or pure motor phenotype were 
treated with IVIg. In Italy, IVIg was also the preferred treat-
ment in patients with fast progressive disease. There was no 
predefined cut of ‘severe disability’ of ‘fast progression’. 
In Serbia, IVIg could only be administered with special 
approval of the Serbian Health Fund. In The Netherlands, 
treatment protocol was changed in 2013 from dexametha-
sone to the combination of IVIg and methylprednisolone as 
the first-line treatment. Dutch patients who were treated after 
2013 were, therefore, not screened for this study. Included 
patients were treated according to the following protocols:
1. Daily prednisone or prednisolone, starting with 
1–1.5 mg/kg body weight during the first 6 weeks, 
tapering to zero during a period of at least 8 months, 
at discretion of the treating neurologist (Serbia and The 
Netherlands). Patients in The Netherlands who did not 
improve were switched to IVIg treatment, while differ-
ent treatment modalities were used as rescue treatment 
in Serbia, dependent on availability. As prednisone is 
metabolized immediately to prednisolone, we will use 
the term prednisolone throughout for both formulations.
2. Oral pulsed dexamethasone 40 mg per day for 4 days 
consecutively each month, during 6 months (The Neth-
erlands). In case of insufficient improvement, patient 
was switched to IVIg treatment.
3. Intravenous pulsed methylprednisolone, starting with 
500 mg daily for 4 days (Italy). Patients who showed 
improvement after the first course of methylprednisolone 
were treated with at least two additional courses (with 
1 or 2 g/month dependent on disease severity). Patients 
who did not improve were switched to IVIg treatment.
  All patients received osteoporosis prophylaxes, con-
sisting of oral calcium and vitamin D, during corticos-
teroid treatment.
Assessment and outcome
Disease severity at baseline was assessed by motor strength 
and the ability to walk with or without aid. Motor strength 
was assessed with the Medical Research Council (MRC) 
sum score (range 0–60; including shoulder abduction, elbow 
flexion, wrist extension, hip flexion, knee extension, and 
ankle dorsiflexion) [13]. A dichotomized value of the modi-
fied ranking scale (mRS) was used to classify patients who 
were able to walk without aid (mRS ≤ 3) or needed assis-
tance while walking (mRS ≥ 4) [14].
The primary outcome was the number of respond-
ers. Responders were defined as patients who showed any 
improvement on motor or sensory impairment as captured 
by the treating neurologist and/or Rankin scale, and who 
did not require additional treatment for CIDP. All patients 
who switched to an alternative treatment, due to insuf-
ficient response, or discontinued treatment prematurely 
due to adverse events, were considered non-responders. 
The primary outcome was assessed 6 months after start of 
treatment.
The secondary outcome was the remission rate in treat-
ment responders, categorized according to the CIDP disease 
activity status (CDAS) [15]. Remission (CDAS 1 and 2) 
was defined as a stable or improving neurological condi-
tion, without the need of ongoing treatment. A relapse was 
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defined as any deterioration warranting new treatment. Other 
outcomes included the probability to reach 5-year remission 
in responders, time to relapse, and adverse events. Charts 
were screened for serious adverse events (SAE) and adverse 
events (AE). AE were considered mild if they did not lead 
to a change in dose or interval and moderate if they led to a 
change in dose or interval during treatment period. SAE was 
defined as an AE that led to discontinuation of treatment, 
permanent damage, and life-threatening complications or 
death.
Statistical analysis
Patient characteristics including gender, age, disease sever-
ity and CIDP variants, were compared between treatment 
groups. Overall analyses were performed by Fisher–Free-
man–Halton t test, one-way ANOVA, two-tailed t test, or 
Kurskal–Wallis tests, where applicable. Post hoc analyses 
were performed on baseline variables using a Fisher–Free-
man–Halton t test or Mann–Whitney U test where applicable.
Response rate and remission rate in treatment respond-
ers were compared between treatment groups using a 
Fisher–Freeman–Halton t test. The probability to reach 
a 5-year remission (CDAS 1) after discontinuation of 
treatment was assessed using Kaplan–Meier curves in 
the treatment responders and in the total cohort. Relaps-
ing patients and non-responders were scored as an event. 
Patients with a follow-up duration shorter than 5 years were 
censored. Between-treatment group comparisons were per-
formed using the log-rank test. Safety was analysed using 
descriptive statistics. A p value of < 0.05 was considered 
statistically significant. Analyses were performed using 
SPSS software.
Results
A total of 196 patients were screened. Of the 67 patients 
screened in Serbia 58 (87%) were included in the study, five 
(7%) received IVIg, two (3%) received plasmapheresis, and 
two (3%) remained untreated. In The Netherlands, 53 CIDP 
patients were screened; 43 (81%) were included in the study, 
8 (15%) received IVIg, and 2 (4%) remained untreated. In 
Italy, 76 treatment naïve CIDP patients were screened; 24 
(32%) were included in the study; 52 (68%) received IVIg 
(Fig. 1).
We included 125 patients; 98 (78%) had typical CIDP, 
while multifocal acquired demyelinating sensory and motor 
neuropathy (MADSAM) was the most common atypical var-
iant (Table 1). Nine patients included in the dexamethasone 
Fig. 1  Screening of treat-
ment naïve CIDP patients and 
treatment response in patients 
initially treated with corticos-
teroids. CS corticosteroids, PE 
plasma exchange
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group and four patients included in the prednisolone group 
were previously described in the PREDICT trial and were 
prospectively followed up [4, 10].
Sixty-seven (54%) patients were treated with daily oral 
prednisolone, 37 (30%) with pulsed oral dexamethasone, 
and 21 (17%) with iv pulsed methylprednisolone (Table 1). 
All patients were treated according to protocol, except for 
three patients. In one patient, prednisolone treatment was 
stopped after 2 months because of substantial improvement. 
One patient who was treated with dexamethasone stopped 
after 5 months, because of substantial improvement and 
minor side effects. Another patient from the dexamethasone 
group had a slow improvement and was, therefore, treated 
for 12 months instead of 6 months. In treatment responsive 
patients, median duration of treatment with prednisolone 
was 15 months (range 2–60), leading to a higher cumula-
tive corticosteroid dose compared to the other treatment 
regimens (Table  2). The prednisolone group included 
more severely affected patients, compared to the other two 
treatment regimens [MRC sum score p = 0.003 and walking 
(un)assisted p = 0.01]. CIDP subtypes were unevenly dis-
tributed between the groups (p = 0.03). Gender and age were 
similar in all groups (Table 1).
Primary outcome
Seventy-five CIDP patients (60%, 95% CI 51–69%) were 
considered responders after corticosteroid treatment; 57% 
after prednisolone, 68% after dexamethasone, and 57% after 
methylprednisolone treatment (Table 2). There was no sig-
nificant difference in response rate between the three treat-
ment regimens (p = 0.56). Response to steroids was seen in 
3 of 12 (25%) patients with multifocal CIDP (MADSAM).
Secondary outcomes
Forty-six of the 75 responders (61%, 95% CI 50–73%) 
remained in remission during a median follow-up of 
Table 1  Patients characteristics at baseline per treatment group
MRC Medical Research Council sum score (six paired muscle groups), MADSAM multifocal acquired demyelinating sensory and motor neu-
ropathy, DADS distal-acquired demyelinating symmetric polyneuropathy
a Post hoc analysis
Prednisolone Dexamethasone Methylprednisolone Total p value
Inclusion, N (%) 67 (54%) 37 (30%) 21 (17%) 125 (100%)
The Netherlands 6 37 0 43
Serbia 57 0 1 58
Italy 4 0 20 24
Male, N (%) 41 (61%) 29 (78%) 15 (71%) 85 (68%) 0.18
Mean age (SD) 51.1 (18) 55.6 (14) 57.1 (14) 53.4 (16) 0.20
Walking unassisted, N (%) 47 (70%) 33 (89%) 20 (95.5%) 100 (80%) 0.01a
Median MRC sum score (range) 50 (34–60) 56 (46–60) 57 (42–60) 53 (34–60) 0.003a
CIDP subtype, N (%) Typical: 58 (87%)
Atypical: 9 (13%)
(MADSAM 3, 
DADS 2, pure 
motor 4)
Typical: 28 (76%)
Atypical: 9 (24%)
(MADSAM 5, pure 
sensory 3, pure motor 
1)
Typical: 12 (57%)
Atypical: 9 (43%)
(MADSAM 4, 
DADS 2, pure 
sensory 3)
Typical: 98 (78%)
Atypical: 27 (22%)
(MADSAM 12, DADS 4, 
pure sensory 6, pure motor 
5)
0.03a
Table 2  Response rate per treatment group and median duration of treatment in treatment responders
MPS methylprednisolone
a Based on 80 kg bodyweight
Prednisolone
N = 67
Dexamethasone
N = 37
MPS
N = 21
Total
N = 125
p value
Treatment response
 Responder, N (%) (95% CI) 38 (57%) (45–69%) 25 (68%) (52–83%) 12 (57%) (34–80%) 75 (60%) (51–69%) 0.56
Median duration of treatment (responders only)
 In months (range) 15 (2–60) 6 (5–12) 6.5 (1–60) 6 (2–60)
Estimated cumulative dose, converted to prednisolone
 Based on 80 kg bodyweight* 10800 mga 6000 mg 9375 mg
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55 months (range 1–197, Table 3). Twenty of twenty-nine 
patients (69%) who experienced a relapse, did so in the first 
6 months after treatment withdrawal (Table 3). The prob-
ability to reach a 5-year remission (CDAS 1) was 55% (95% 
CI 44–70%) in patients who responded to corticosteroid 
treatment (N = 75), with no significant difference between 
the treatment regimens (Fig.  2). Converted to the total 
cohort (N = 125), the probability to reach a 5-year remis-
sion after corticosteroids treatment was 33% (Figure not 
shown). Thirty-one of the fifty non-responders were treated 
with IVIg of whom 21 (68%) showed a favourable response 
to IVIg (Fig. 1). Response rate improved to 91% (96/106), 
when IVIg was given as a subsequent treatment in case cor-
ticosteroid treatment was insufficient. Eleven non-responders 
Table 3  Proportion of patients in remission and median time to relapses in treatment responders
MPS methylprednisolone
Treatment responders Prednisolone
N = 38
Dexamethasone
N = 25
MPS
N = 12
Total
N = 75
p value
Patients in remission, N (%) (95% CI) 25 (66%) (50–82%) 16 (64%) (44–84%) 5 (42%) (9–74%) 46 (61%) (50–73%) 0.343
Median follow-up of patients reaching 
remission (range in months)
31 (1–180) 93 (17–197) 19 (2–45) 55 (1–197)
Median time to relapse (range in months) 0 (0–30) 6 (0–51) 0 (0–12) 4 (0–51)
< 6 months, N 9 6 5 20
> 6 months, N (range in months) 4 (7–30) 3 (24–51) 2 (8–12) 9 (7–51)
Fig. 2  Probability of remission 
after corticosteroid discon-
tinuation in treatment respond-
ers. Data were censored for 
shorter follow-up duration than 
60 months. The MPS group 
was analysed but removed from 
figure as the curve was mislead-
ing due to the small proportion 
of responders and large effect of 
censoring due to short follow-up 
in most patients
Follow up in months
Number at risk
0 10 20 30 40 50 60 probability of 5-
year remission
(95% CI)
P-value
Tr
ea
tm
en
t
Prednisolone 38 19 17 13 12 12 12 59.1% (44-80%)
0.126Dexamethasone 25 19 18 17 14 12 11 61.4% (44-85%)
Methylprednisolone 12 4 2 2 1 0 0 32.1% (13-80%)
Total 75 42 37 32 27 24 23 55.3% (44-70%)
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did not receive an alternative treatment due to unavailability 
of IVIg or plasma exchange, five patients received corticos-
teroids in a different regimen, one patient received plasma 
exchange, and two patients were lost to follow up (Fig. 1). 
Eight of the nine MADSAM non-responders had a favour-
able response to IVIg.
Adverse events
Moderate AE were reported in ten patients (8%); nine 
patients from the prednisolone group and one from the dex-
amethasone group. Adverse events included hypertension, 
diabetes mellitus de novo, glaucoma, depression, cushingoid 
appearance, and gastro-intestinal complaints. SAE occurred 
in two patients, both in the prednisolone group: one case of 
severe hypertension and one acute myocardial infarction.
Discussion
Response
The three different corticosteroid regimens had a similar 
response rate of approximately 60%. Reported response rates 
of various corticosteroid treatment regimens vary between 
50 and 90%, which is in line with our results [7–10, 12, 
16–18]. A large Italian retrospective study found a similar 
response rate of 64% after prednisolone treatment, which 
was not significantly lower than the response rate of IVIg 
(78%) [12]. We found a relatively poor response to corti-
costeroids in patients with MADSAM (25%) compared to 
the literature [19].
Remission
In this study, we found a remission rate of 61% (46/75) 
in the treatment responders, with a median follow-up of 
55 months (range 1–197). Importantly, two-third of patients 
who relapsed, did so in the first 6 months after treatment 
withdrawal. It might be reassuring to patients that the chance 
of relapse decreases over time.
The probability to reach a 5-year remission (CDAS 1) 
was 55% (95% CI 44–70%) in patients who responded to 
corticosteroid treatment (N = 75) and 33% in the total cohort 
(N = 125). There were no significant differences between the 
three corticosteroid regimens in the remission rate and the 
probability of 5-year remission.
Remission rates found in our study are higher than the 
long-term remission rates previously reported in smaller 
studies. During a median follow-up of 42 months in the 
IMC trial, remission rates were 15% (2/13) after intrave-
nous methylprednisolone and 4% (1/28) after IVIg [5]. 
However, not all patients in this trial were treatment naïve, 
which might have led to selection bias to patients with more 
chronic disease course. The prospective extension study of 
the PREDICT trial, which included only treatment naïve 
patients, showed a remission rate of 25% (6/24) in pulsed 
dexamethasone and 12.5% (2/16) in prednisolone, after a 
mean follow-up period of 4.5 year [4].
Evidence about long-term remission after withdrawal of 
IVIg treatment is also limited. In the extension phase of the 
ICE trial, 57 CIDP patients who responded to IVIg treat-
ment were re-randomized to continue IVIg treatment or to 
switch to placebo. After 24 weeks of follow-up, 55% of the 
patients treated with placebo were still in remission [20]. 
Two retrospective studies provide remission data in patients 
treated with IVIg. Querol et al. described a cohort of 86 
CIDP patients treated with IVIg treatment. After a mean fol-
low-up of 3.9 years, 26% was in remission, 65% was still in 
need of maintenance treatment and 9% were non-responsive 
to IVIg [21]. Kuitwaard et al. found a remission rate of 40% 
(86/214) in CIDP patients responsive to IVIg treatment, with 
a mean follow-up duration of 5.2 years [22]. The remission 
rate found in our study is higher and supports the hypoth-
esis that corticosteroids can lead to long-term remission in 
CIDP more often compared to IVIg. However, comparison 
between these retrospective studies with possible selection 
bias should be performed with caution. In addition, chance 
of remission might also be related to certain clinical features, 
such as symmetrical distribution or a relapsing–remitting 
course [6].
IVIg in non‑responders
When corticosteroid therapy failed and IVIg was given 
as a subsequent treatment, response rate improved to 91% 
(96/106). Cocito et al. found that 86% (108/125) of patients 
had a good response to corticosteroids, or to subsequent 
IVIg treatment, in case the initial corticosteroids treatment 
failed [12]. Alternatively, Kuitwaard et al. studied CIDP 
patients initially treated with IVIg [22]. They found a simi-
lar response rate of 94% (234/248) in patients who had a 
good response to the initial IVIg treatment, or who received 
corticosteroids as subsequent treatment when IVIg failed. 
Both corticosteroids and IVIg treatment are considered the 
first-line treatment. In general, IVIg is regarded to have 
slightly higher response rates than corticosteroids [12, 16, 
22]. However, the results from these studies suggest that 
most patients respond to at least one of both treatments, 
and that the overall response rate does not depend on the 
sequence of treatments.
Adverse events
Moderate AE occurred in 8% of patients of whom two 
patients had an SAE. Most of these adverse events were seen 
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in the prednisolone group, which was the largest group of the 
three treatment regimens. Another possible explanation for 
the number of adverse events in the prednisolone group was 
the higher cumulative dose of prednisolone. The number of 
mild AE, which did not lead to a change in dose or interval, 
was low. Given the retrospective nature of this study, we 
suspect that mild AE were underreported and, therefore, not 
representative for the true number of mild AE occurring 
during corticosteroid treatment.
A known and serious side effect from long-term use of 
corticosteroids is osteoporosis. The American College of 
Rheumatology Guideline for the Prevention and Treatment 
of Glucocorticoid-Induced Osteoporosis recommends to 
treat all patients with calcium and vitamin D when start-
ing long-term corticosteroid treatment [23]. Patients in this 
study were all treated accordingly. No osteoporotic fractures 
occurred in our cohort, but DEXA scans were not performed 
routinely to check for the occurrence of osteoporosis.
Strength and limitations of our study
The main limitation of this study is the retrospective nature 
and lack of standardized evaluation and follow-up of 
patients. Moreover, there were no predefined selection crite-
ria for the first-line treatment other than severe disability and 
contraindication for corticosteroids that can be interpreted 
in different ways. This could have led to selection bias. In 
Italy, for example, a majority of patients were treated with 
IVIg in contrast with Serbia and the Netherlands. Although 
‘fast progression’ was used as an additional criterion for use 
of IVIg, it is unlikely that this criterion explains the large 
differences between the percentages of patients treated with 
IVIg in the three centres. In Serbia, IVIg is only available 
with special approval of the Serbian Health Fund; there-
fore, most patients were treated with prednisolone. This 
might explain why the prednisolone group contained more 
severely impaired patients. It is, however, unclear whether 
severity of disability is a determinant of treatment response 
or remission [24]. As the treatment regimens were largely 
centre specific, other confounders could have attributed to 
the reported response and remission rates, including health 
care infrastructure and the availability of physiotherapy and 
rehabilitation.
Another possible limitation is the difference in treatment 
duration between the different corticosteroid regimens. The 
median treatment duration of the prednisolone group was 
15 months, leading to a higher cumulative dose compared 
to the dexamethasone and methylprednisolone groups. 
Alternatively, in the methylprednisolone group, the treating 
neurologist decided after a single course of methylpredni-
solone whether to continue methylprednisolone or to switch 
to IVIg, based on clinical improvement of the patient. The 
decision whether dexamethasone or prednisolone treatment 
was effective or not was made after several months of treat-
ment. Previous studies have shown that time to improve 
after corticosteroids can take up to several months. Meas-
uring outcome after four weeks in the methylprednisolone 
group might have been too early for some patients and might 
have caused an underestimation of the response rate [8, 10]. 
Despite the limitations of a retrospective study, we believe 
that these results provide insight in everyday CIDP practice 
and will be helpful for treating neurologists, in both high-
income and low-income countries. Only a few comparative 
studies are available regarding corticosteroid treatment in 
CIDP and new randomized trails are not likely to be under-
taken. To our knowledge, this is the largest study comparing 
different corticosteroids regimens in treatment naïve CIDP 
patients.
Conclusions
We conclude that the response rate of corticosteroids as the 
first-line treatment for CIDP is 60%, without a significant 
difference between the three regimens. About a third of 
all patients will remain in remission after treatment with 
corticosteroids. Most patients who experience a relapse 
do so in the first 6 months after discontinuation of treat-
ment. Although there were no differences in response and 
remission rate between the regimens, pulsed corticoster-
oids regimens have lower cumulative doses and possibly 
less long-term adverse events. A treatment protocol with 
corticosteroids, followed by IVIg as a subsequent treatment 
in case corticosteroid treatment is insufficient, can lead to 
improvement in 9 out of 10 patients.
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